ONCOLOGY

——————— A major regulatory milestone brings ODI-2001 one step closer to delivering a new generation of personalised immunotherapy to patients. Odimma Therapeutics, a biotechnology company developing next-generation personalized cancer immunotherapies, today announced the submission of a first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for ODI-2001, its innovative multi-component therapeutic platform. This first-in-human clinical trial…

——————— Odimma Therapeutics announced the presentation of new preclinical data supporting ODI-2001, the company’s personalized combinatorial immunotherapy platform, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting held in Houston, Texas from November 6–10, 2024. The data presented demonstrate antitumoral activity across multiple syngeneic mouse tumor models, including the highly aggressive 4T1 breast…

——————— Odimma Therapeutics will participate in BIO-Europe Spring 2024, taking place in Barcelona from March 18–20, 2024. The event brings together biotechnology companies, investors, pharmaceutical leaders and innovation partners from across the international life sciences ecosystem. Participation in BIO-Europe Spring reflects Odimma Therapeutics’ continued commitment to expanding strategic collaborations and increasing the international visibility of…

——————— Odimma Therapeutics has joined the Paris Saclay Cancer Cluster (PSCC), the first European biocluster dedicated exclusively to oncology innovation. As part of this initiative, Odimma Therapeutics will participate in the PSCC Innovation Forum 2024 taking place on February 5, 2024, under the patronage of President Emmanuel Macron. The Paris Saclay Cancer Cluster brings together…